Medmira (MIR) AI Stock Analysis

• Market Cap: C$54.42M
• Dividend Yield: N/A
• Average Volume (3M): 32.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: -33.66%
• EPS Growth: -48.89%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 697,666,140
• 10 Day Avg. Volume: 21,629
• 30 Day Avg. Volume: 32,698
• PEG Ratio: 2.41
• Price to Book (P/B): -2.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Medmira's overall stock score is heavily influenced by its poor financial performance, which poses significant risks. Technical analysis and valuation further emphasize the challenges, despite positive corporate events suggesting potential strategic improvements.

Medmira Business Overview & Revenue Model

Company Description

Medmira Inc. is a biotechnology company that operates in the healthcare sector, specializing in the development and manufacturing of rapid diagnostic solutions. The company is headquartered in Halifax, Canada, and is known for its expertise in creating point-of-care testing products. Medmira’s core offerings include diagnostic tests for infectious diseases such as HIV, Hepatitis, and Syphilis, leveraging its patented Rapid Vertical Flow (RVF) Technology.

How the Company Makes Money

Medmira makes money through the sale of its rapid diagnostic test kits to healthcare providers, clinics, and distributors worldwide. The company's revenue model is primarily based on product sales, with its rapid tests being the key revenue streams. Medmira collaborates with various distribution partners to expand its market reach and accessibility of its products. Additionally, the company seeks to enhance its earnings through strategic partnerships and licensing agreements that allow it to leverage its proprietary technology in new markets or applications.

Medmira Financial Statement Overview

Summary

Medmira faces significant financial challenges, with declining revenue growth, negative gross profit margin, and negative net profit margin. The balance sheet shows high leverage and negative equity, while cash flow analysis reveals negative free cash flow and reliance on external funding.

Income Statement

Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.

Balance Sheet

The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	254.30K	412.57K	432.53K	952.13K	2.14M	919.07K
Gross Profit	178.85K	226.49K	-434.91K	304.03K	1.72M	572.28K
EBITDA	-3.24M	-2.13M	-1.58M	-1.07M	185.30K	-1.13M
Net Income	-4.66M	-3.33M	-2.68M	-1.83M	-675.80K	-2.05M
Balance Sheet
Total Assets	3.78M	6.07M	3.65M	3.83M	3.89M	3.40M
Cash, Cash Equivalents and Short-Term Investments	18.28K	2.10M	13.18K	33.46K	-2.30M	401.86K
Total Debt	10.16M	9.56M	9.27M	8.30M	11.54M	11.91M
Total Liabilities	25.30M	24.11M	18.68M	16.19M	19.61M	18.96M
Stockholders Equity	-21.52M	-18.04M	-15.03M	-12.36M	-15.72M	-15.56M
Cash Flow
Free Cash Flow	-4.14M	-3.68M	-1.27M	-1.95M	-541.19K	-417.78K
Operating Cash Flow	-3.39M	-2.94M	-1.27M	-1.88M	-504.64K	-315.90K
Investing Cash Flow	-746.19K	-742.53K	-1.27K	-69.72K	-36.55K	-101.88K
Financing Cash Flow	1.25M	5.77M	1.25M	1.99M	139.32K	730.74K

Medmira Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	79 Outperform	C$71.56M	18.19	14.51%	―	28.97%	―
MBX	70 Neutral	C$42.17M	25.43	5.32%	―	-4.67%	-60.94%
Sector *	57 Neutral	£4.84B	6.62	-61.44%	5.44%	33.02%	6.17%
ONC	43 Neutral	$155.53M	―	-211.24%	―	―	0.10%
MIR	43 Neutral	C$54.42M	―		―	-33.66%	-48.89%
SVA	33 Underperform	C$52.56M	―	248.46%	―	―	32.71%
HBP	33 Underperform	C$71.93M	―	685.26%	―	―	-50.29%

Medmira Corporate Events

MedMira Launches Clinical Trial for HIV/Syphilis Self-Test in Canada

MedMira has launched a clinical trial for its Multiplo® TP/HIV self-test in Canada, marking a significant step in addressing the rising cases of HIV and syphilis in the country. The trial, supported by Health Canada and funded by the Canadian Institutes of Health Research, aims to bring the self-test to communities in need, bypassing traditional regulatory steps. This initiative is expected to empower individuals with privacy and control over their health, potentially reducing the spread of these infections by providing immediate results and facilitating access to care.

MedMira Reports Q2 FY2025 Results, Advances in STI and HIV Testing

MedMira Inc. reported its second quarter financial results for FY2025, highlighting significant advancements in product launches and regulatory progress. The company introduced its Health Canada approved Multiplo® TP/HIV and Reveal® Rapid HIV Test in Canada, generating strong demand and working towards expanding its STI product portfolio. MedMira is also pursuing regulatory approvals in the U.S. for its Reveal® G4 HIV-1/2 rapid test and is in discussions to accelerate the commercialization of its MiROQ technology. Despite increased operating expenses due to clinical trials, these developments position MedMira for enhanced market access and potential growth.

MedMira Partners with Lovell to Enhance Federal Access to Rapid HIV Testing

MedMira Inc. has partnered with Lovell Government Services to expand access to its Reveal® G4 HIV-1/2 rapid test within federal healthcare systems, including the Veterans Health Administration and the Military Health System. This collaboration allows MedMira to leverage Lovell’s status as a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, facilitating the procurement of their products through various federal contracting systems. The partnership is expected to enhance MedMira’s market reach and streamline the acquisition process for government agencies, thereby supporting federal procurement goals and improving healthcare delivery for veterans.